Cancer immunotherapy strategies leveraging the body’s own immune system against cancer cells have gained significant attention due to their remarkable therapeutic efficacy. Several immune therapies have been approved for clinical use while expanding the modalities of cancer therapy. However, they are still not effective in a broad range of cancer patients because of the typical immunosuppressive microenvironment and limited antitumor immunity achieved with the current treatment. Novel approaches, such as nanoparticle-mediated cancer immunotherapies, are being developed to overcome these challenges. Various types of nanoparticles, including liposomal, polymeric, and metallic nanoparticles, are reported for the development of effective cancer therapeutics. Metallic nanoparticles (MNPs) are one of the promising candidates for anticancer therapy due to their unique theranostic properties and are thus explored as both imaging and therapeutic agents. In addition, MNPs offer a dense surface functionalization to target tumor tissue and deliver genetic, therapeutic, and immunomodulatory agents. Furthermore, MNPs interact with the tumor microenvironment (TME) and regulate the levels of tumor hypoxia, glutathione (GSH), and reactive oxygen species (ROS) for remodulation of TME for successful therapy. In this review, we discuss the role of nanoparticles in tumor microenvironment modulation and anticancer therapy. In particular, we evaluated the response of MNP-mediated immune cells, such as dendritic cells, macrophages, T cells and NK cells, against tumor cells and analyzed the role of MNP-based cancer therapies in regulating the immunosuppressive environment.
Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, has generated substantial interest in cancer therapy. Various methods have been developed to induce ferroptosis in tumor cells, including approved drugs, experimental compounds, and nanomedicine formulations. Unlike apoptosis, ferroptosis presents unique molecular and cellular features, representing a promising approach for cancers resistant to conventional treatments. Recent research indicates a strong link between ferroptosis and the tumor immune microenvironment, suggesting the potential of ferroptosis to trigger robust antitumor immune responses. Multiple cellular metabolic pathways control ferroptosis, including iron, lipid, and redox metabolism. Thus, understanding the interaction between tumor metabolism and ferroptosis is crucial for developing effective anticancer therapies. This review provides an in-depth discussion on combining inorganic nanoparticles with cancer therapies such as phototherapy, chemotherapy, radiotherapy, and immunotherapy, and the role of ferroptosis in these combination treatments. Furthermore, this paper explores the future of tumor treatment using nanomedicine, focusing on how inorganic nanoparticles can enhance ferroptosis in tumor cells and boost antitumor immunity. The goal is to advance ferroptosis-based nanomedicine from the laboratory to clinical applications.